TECH
Bio-Techne Corporation57.44
-1.25-2.13%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q2 '26
Q&A spotlights underlying momentum
Q&A unpacked underlying mid-single-digit growth ex-cell therapy and OEM timing headwinds, building from 1% in Q1 to 3% in Q2 toward stronger Q4 momentum. Management detailed biotech funding's six-month revenue lag, China acceleration from CDMO/CRO/biotech deals, and spatial pull-through at $45k per Comet aiming for $90k via multiomics. Organoids hit $50M run rate amid animal-free launches. AI emerged as tailwind for complex reagents. Active M&A pipeline targets antibodies, cell therapy. Analysts probed margins, recovery timing—answered directly, cautiously optimistic. Q&A adds end-market color. Watch biotech rebound.
Key Stats
Market Cap
8.95BP/E (TTM)
117.22Basic EPS (TTM)
0.49Dividend Yield
0.01%Recent Filings
8-K
Leadership change at Bio-Techne
Bio-Techne announced Dr. Matt McManus's transition from President of Diagnostics and Spatial Biology Segment effective March 1, 2026, with support for handover. Steve Crouse, current SVP of Analytical Solutions, steps in with proven growth record from protein platforms. New deal offers $505,000 base, 75% target bonus. Smooth internal shift.
8-K
Flat revenue, EPS gains
Bio-Techne posted Q2 FY2026 revenue of $295.9M, flat year-over-year on organic basis amid held-for-sale impacts. GAAP EPS rose to $0.24 from $0.22; adjusted hit $0.46, with margins expanding to 31.1% via cost controls and Exosome divestiture. Board declared $0.08/share dividend, payable February 27. Steady pharma demand persists.
10-Q
Q2 FY2026 results
Bio-Techne's Q2 FY2026 sales held flat at $295.9M y/y yet operating income jumped 15% to $54.5M, with gross margin dipping to 64.6% on product mix shifts. Protein Sciences grew 2% to $215.1M while Diagnostics and Spatial Biology improved margins to 10.4% from 3.9%, fueled by Exosome divestiture and cost cuts. Operating cash flow hit $110.0M YTD; debt fell to $260M with $740M revolver room. Cash sits at $172.9M. Restructuring persists. Litigation costs could spike.
8-K
Q1 revenue dips 1%, margins up
Bio-Techne reported Q1 FY2026 revenue down 1% to $286.6M, with GAAP EPS rising to $0.24 from $0.21; adjusted EPS held flat at $0.42. Completed Exosome Diagnostics divestiture to sharpen focus on growth pillars, lifting adjusted operating margin to 29.9%. Declared $0.08/share dividend, payable November 28. All nine director nominees elected.
10-Q
Q1 FY2026 results
Bio-Techne's Q1 FY2026 sales dipped 1% y/y to $286.6M while gross margin expanded to 65.6% from 63.2%, driving operating income up 19% to $47.7M and diluted EPS to $0.24 from $0.21 on fewer shares (156.4M vs 161.1M). Protein Sciences edged down 1% to $202.2M, yet Diagnostics and Spatial Biology improved margins to 11.2% from 5.1% post-Exosome divestiture for $15M (stock/cash, $9M note receivable maturing 2029). Operating cash flow came in at $27.6M, with capex $5.4M; debt fell to $300M ($1B revolver, $700M available, matures 2027). Cash sits at $145M. Litigation costs remain unpredictable.
A
Agilent Technologies, Inc.
139.19-1.41
BIAF
bioAffinity Technologies, Inc.
1.38-0.10
BIO
Bio-Rad Laboratories, Inc.
302.02-5.90
BRKR
Bruker Corporation
44.96-0.71
DHR
Danaher Corporation
224.70-3.83
ILMN
Illumina, Inc.
131.56-3.36
LAB
Standard BioTools Inc.
1.49-0.02
SEER
Seer, Inc.
1.84+0.02
TMO
Thermo Fisher Scientific Inc
570.16-5.75
TWST
Twist Bioscience Corporation
31.13+0.06